A PHASE II TRIAL OF ERLOTINIB FOR PREVIOUSLY TREATED JAPANESE PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER HARBORING EGFR MUTATIONS: RESULTS OF THE CENTRAL JAPAN LUNG STUDY GROUP TRIAL (CJLSG0904).

被引：0

作者：

Hase, Tetsunari ^{[1
]}

Morise, Masahiro ^{[1
]}

Taniguchi, Hiroyuki ^{[2
]}

Shindoh, Joe ^{[3
]}

Kojima, Eiji ^{[4
]}

Tanikawa, Yoshimasa ^{[5
]}

Suzuki, Ryujiro ^{[6
]}

Ogasawara, Tomohiko ^{[7
]}

Yamada, Yoshiyuki ^{[8
]}

Ando, Masahiko ^{[9
]}

Kondo, Masashi ^{[1
]}

Saito, Hiroshi ^{[10
]}

Hasegawa, Yoshinori ^{[1
]}

机构：

[1] Nagoya Univ, Grad Sch Med, Dept Resp Med, Nagoya, Aichi 4648601, Japan

[2] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Aichi, Japan

[3] Ogaki Municipal Hosp, Dept Resp Med, Gifu, Japan

[4] Komaki Municipal Hosp, Dept Resp Med, Gifu, Japan

[5] Toyota Kosei Hosp, Dept Resp Med & Allergy, Toyota, Japan

[6] Toyohashi Municipal Hosp, Dept Resp Med, Toyohashi, Aichi, Japan

[7] Japanese Red Cross Nagoya Daini Hosp, Dept Resp Med, Nagoya, Aichi, Japan

[8] Konan Kosei Hosp, Dept Resp Med, Konan, Aichi, Japan

[9] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi, Japan

[10] Aichi Hosp, Aichi Canc Ctr, Dept Resp Med, Nagoya, Aichi, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷

关键词：

erlotinib; phase II; EGFR;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.10-041

引用

页码：S582 / S583

页数：2

共 50 条

[1] Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in Kyushu (LOGiK0803)
Yamada, Kazuhiko
Takayama, Koichi
Kawakami, Satoru
Saruwatari, Kouichi
Morinaga, Ryotaro
Harada, Taishi
Aragane, Naoko
Nagata, Shuya
Kishimoto, Junji
Nakanishi, Yoichi
Ichinose, Yukito
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2013, 43 (06) : 629 - 635
[2] PHASE II TRIAL OF ERLOTINIB IN PREVIOUSLY TREATED PATIENTS WITH NON-SMALL CELL LUNG CANCER
Okano, Yoshio
Shinohara, Tsutomu
Machida, Hisanori
Hatakeyama, Nobuo
Takeuchi, Eiji
Doi, Hiroyuki
Kubota, Tetsuya
Yokoyama, Akihito
Ogushi, Fumitaka
JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1175 - S1176
[3] Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802)
Yamada, Kazuhiko
Azuma, Koichi
Takeshita, Masafumi
Uchino, Junji
Nishida, Chinatsu
Suetsugu, Takayuki
Kondo, Akira
Harada, Taishi
Eida, Hirofumi
Kishimoto, Junji
Eriguchi, Goki
Takayama, Koichi
Nakanishi, Yoichi
Sugio, Kenji
ANTICANCER RESEARCH, 2016, 36 (06) : 2881 - 2887
[4] Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial
Fan, Yun
Chen, Jianhua
Zhou, Chengzhi
Wang, Huijuan
Shu, Yongqian
Zhang, Jacky
Hua, Hairui
Huang, Dennis Chin-Lun
Zhou, Caicun
LUNG CANCER, 2020, 147 : 209 - 213
[5] Phase II Study of Erlotinib in Japanese Patients with Advanced Non-small Cell Lung Cancer
Takahashi, Toshiaki
Yamamoto, Nobuyuki
Nukiwa, Toshihiro
Mori, Kiyoshi
Tsuboi, Masahiro
Horai, Takeshi
Masuda, Noriyuki
Eguchi, Kenji
Mitsudomi, Tetsuya
Yokota, Soichiro
Segawa, Yoshihiko
Ichinose, Yukito
Fukuoka, Masahiro
Saijo, Nagahiro
ANTICANCER RESEARCH, 2010, 30 (02) : 557 - 563
[6] A Phase II Trial of Erlotinib Monotherapy in Pretreated Patients with Advanced Non-small Cell Lung Cancer Who Do Not Possess Active EGFR Mutations Okayama Lung Cancer Study Group Trial 0705
Yoshioka, Hiroshige
Hotta, Katsuyuki
Kiura, Katsuyuki
Takigawa, Nagio
Hayashi, Hidetoshi
Harita, Shingo
Kuyama, Shoichi
Segawa, Yoshihiko
Kamei, Haruhito
Umemura, Shigeki
Bessho, Akihiro
Tabata, Masahiro
Tanimoto, Mitsune
JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (01) : 99 - 104
[7] A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
Clement-Duchene, Christelle
Natale, Ronald B.
Jahan, Thierry
Krupitskaya, Yelena
Osarogiagbon, Raymond
Sanborn, Rachel E.
Bernstein, Eric D.
Dudek, Arkadiusz Z.
Latz, Jane E.
Shi, Peipei
Wakelee, Heather A.
LUNG CANCER, 2012, 78 (01) : 57 - 62
[8] A phase I trial of afatinib and bevacizumab in chemo-naive patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404
Ninomiya, Takashi
Nogami, Naoyuki
Kozuki, Toshiyuki
Harada, Daijiro
Kubo, Toshio
Ohashi, Kadoaki
Kuyama, Shoichi
Kudo, Kenichiro
Bessho, Akihiro
Fukamatsu, Nobuaki
Fujimoto, Nobukazu
Aoe, Keisuke
Shibayama, Takuo
Sugimoto, Keisuke
Takigawa, Nagio
Hotta, Katsuyuki
Kiura, Katsuyuki
LUNG CANCER, 2018, 115 : 103 - 108
[9] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
Yang, J. J.
Zhou, Q.
Yan, H. H.
Zhang, X. C.
Chen, H. J.
Tu, H. Y.
Wang, Z.
Xu, C. R.
Su, J.
Wang, B. C.
Jiang, B. Y.
Bai, X. Y.
Zhong, W. Z.
Yang, X. N.
Wu, Y. L.
BRITISH JOURNAL OF CANCER, 2017, 116 (05) : 568 - 574
[10] A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations
J J Yang
Q Zhou
H H Yan
X C Zhang
H J Chen
H Y Tu
Z Wang
C R Xu
J Su
B C Wang
B Y Jiang
X Y Bai
W Z Zhong
X N Yang
Y L Wu
British Journal of Cancer, 2017, 116 : 568 - 574

← 1 2 3 4 5 →